Differential penetration of raltegravir throughout gastrointestinal tissue: Implications for eradication and cure

AIDS

Volumn 27, Issue 9, 2013, Pages 1413-1419

  Patterson, Kristine B ^a   Prince, Heather A ^a   Stevens, Trenton ^a   Shaheen, Nicholas J ^a   Dellon, Evan S ^a   Madanick, Ryan D ^a   Jennings, Steven ^b   Cohen, Myron S ^a   Kashuba, Angela D M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Gut associated lymphoid tissue; HIV cure; Latency; Pharmacokinetics; Raltegravir

Indexed keywords

RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; COLONOSCOPY; DRUG BLOOD LEVEL; DRUG PENETRATION; HUMAN; ILEUM; INTESTINE LYMPHATIC TISSUE; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECTUM; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL TRACT; HIV; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PYRROLIDINONES; VIRAL LOAD; YOUNG ADULT;

EID: 84879084001     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835f2b49     Document Type: Article

References (45)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19.
3. Hogg R, Lima V, Sterne JA, Grabar S, Bonarek M, The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
5. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295.
6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(R) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873.
7. Hicks CB, Gay C, Ferrari G. Acute HIV infection: the impact of antiretroviral treatment on cellular immune responses. Clin Exp Immunol 2007; 149:211-216.
8. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
9. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
10. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284-1290.
11. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
12. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105:16725-16730.
13. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
14. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179:849-858.
15. Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A 2003; 100:12955-12960.
16. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5:95-106.
17. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4R cell infection. PLoS One 2010; 5:1-4.
18. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4R T cells. AIDS 2008; 22:1131-1135.
19. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
20. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555.
21. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4R T cell model without inducing global T cell activation. J Virology 2011; 85:6060-6064.
22. Havlir DV. HIV integrase inhibitors: out of the pipeline and into the clinic. N Engl J Med 2008; 359:416-418.
23. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 2011; 203:1484-1490.
24. Brown KC, Patterson KB, Jennings SH, Malone SA, Shaheen NJ, Asher Prince HM, et al. Single and multiple dose pharma-cokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr 2012; 61:138-144.
25. Mardirossian G, Tagesson M, Blanco P, Bouchet LG, Stabin M, Yoriyaz H, et al. A new rectal model for dosimetry applications. J Nucl Med 1999; 40:1524-1531.
26. Jones A, Talameh J, Patterson K, Rezk N, Prince H, Kashuba ADM. First-dose and steady-state pharmacokinetics of raltegravir in the genital tract of HIV uninfected women. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 2009 April 15-17, 2009; Amsterdam, The Netherlands.
27. Patterson KB, Prince HA, White N, Wang R, Jones A, Kashuba ADM. Pharmacokinetics of raltegravir in the blood plasma and genital tract of HIV-positive and HIV-negative women. XVIII International AIDS Conference; 2010 July 18-23, 2010; Vienna, Austria.
28. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88:598-609.
29. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
30. Fletcher C. Pharmacologic analysis of lymphatic reservoirs of HIV Infection. Fifth International Conference on HIV Persistence During Therapy; 2011 December 6-9, 2011; St. Maarten, West Indies.
31. Cohen J. HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 2011; 334:1614.
32. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546-553.
33. Robbins BL, Nelson SR, Fletcher CV. A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts. J Pharm Biomed Anal 2012; 70:378-387.
34. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, et al. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromat B 2006; 843:147-156.
35. Deeks SG. HIV: shock and kill. Nature 2012; 487:439-440.
36. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
37. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515.
38. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-2321.
39. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
40. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4R T cell response. J Infect Dis 2011; 203:960-968.
41. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
42. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-919.
43. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-1561.
44. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948.
45. Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012; 8:e1002774.